for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Arrowhead Pharmaceuticals Inc

ARWR.OQ

Latest Trade

35.95USD

Change

-0.65(-1.78%)

Volume

1,039,104

Today's Range

35.60

 - 

38.74

52 Week Range

10.42

 - 

38.74

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
36.60
Open
36.89
Volume
1,039,104
3M AVG Volume
29.08
Today's High
38.74
Today's Low
35.60
52 Week High
38.74
52 Week Low
10.42
Shares Out (MIL)
95.30
Market Cap (MIL)
3,426.07
Forward P/E
48.15
Dividend (Yield %)
--

Next Event

Q4 2019 Arrowhead Pharmaceuticals Inc Earnings Release

Latest Developments

More

Arrowhead Collaborator Janssen Begins Reef-1 Phase 2B Combination Study In Patients With Chronic Hepatitis B Infection

Arrowhead Pharmaceuticals Qtrly Earnings Per Share $0.21

Arrowhead Pharmaceuticals Receives Orphan Drug Designation For ARO-ANG3

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.

Industry

Biotechnology & Drugs

Contact Info

225 S Lake Ave Ste 1050

+1.626.3043400

http://arrowheadpharma.com/

Executive Leadership

Douglass Bruce Given

Chairman of the Board

Christopher Richard Anzalone

President, Chief Executive Officer, Director

Kenneth Allen Myszkowski

Chief Financial Officer

Bruce D. Given

Chief Operating Officer

Patrick C. O'Brien

General Counsel

Key Stats

1.83 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.2K
EPS (USD)

2016

-1.340

2017

-0.470

2018

-0.650

2019(E)

0.747
Price To Earnings (TTM)
78.64
Price To Sales (TTM)
25.05
Price To Book (MRQ)
15.13
Price To Cash Flow (TTM)
68.39
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
25.52
Return on Equity (TTM)
20.24

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up